BGNE Overview
Upcoming Projects (BGNE)
-
A look at the developing BTK inhibitor landscape for CLL and SLL with a primary focus on the the ASH updates from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo
Tickers: BGNE, AZN, NRIX
Scheduled For: Feb 05, 2025 at 04:00 PM EST -
A second look at the developing BTK inhibitor landscape for CLL and SLL with a primary focus on the the ASH updates from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo.
Tickers: BGNE, AZN, NRIX
Scheduled For: Feb 05, 2025 at 05:00 PM EST
Executed Projects (BGNE)
-
Discussing the Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Tickers: ZYME, JAZZ, BGNE
Executed On: Oct 11, 2024 at 04:30 PM EDT -
A discussion of BTK inhibitors in Chronic Lymphocytic Leukemia, including zanabrutinib and NX-5948
Tickers: BGNE, ABBV, NRIX
Executed On: Jan 26, 2024 at 02:00 PM EST -
Discussing BeiGene's anti–PD-1 antibody, tislelizumab in gastric adenocarcinoma and the results of the RATIONALE-305 study presented at ESMO 2023
Ticker: BGNE
Executed On: Oct 26, 2023 at 11:00 AM EDT -
Digging into the the results from the Phase 3 RATIONALE-306 study, regarding BeiGene's Tislelizumab plus chemotherapy as first-line treatment for Esophageal Squamous Cell Carcinoma (ESCC)
Ticker: BGNE
Executed On: Oct 16, 2023 at 02:00 PM EDT -
Digging into the final analysis from the Phase 3 ALPINE trial of Zanubrutinib (BRUKINSA) for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Ticker: BGNE
Executed On: Nov 14, 2022 at 05:30 PM EST
Expired Projects (BGNE)
Upcoming & Overdue Catalysts (BGNE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BGNE)
-
Beigene's(BGNE) Phase 1b data of Zanubrutinib and Obinutuzumab in Relapsed/Refractory Follicular Lymphoma to be presented at ICML
Ticker: BGNE
Occurred on: Jun 20, 2019 -
Preliminary Results Presented from Beigene's (BGNE) Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma
Ticker: BGNE
Occurred on: Sep 21, 2018
Strategic Initiatives (BGNE)
-
Leap Therapeutics (LPTX) and BeiGene (BGNE) Announce Exclusive Option and License Agreement for DKN-01 + $27 Million Equity Financing
Tickers: LPTX, BGNE
Announcement Date: Jan 03, 2020
